Vaxart (NASDAQ: VXRT) CMO shares withheld to cover RSU tax obligations
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vaxart, Inc. Chief Medical Officer James F. Cummings reported a routine tax-withholding transaction involving company stock. On March 28, 2026, 3,292 shares of Common Stock were withheld by Vaxart at $0.65 per share to cover income tax obligations from vested RSUs.
After this withholding, Cummings directly holds 924,177 shares of Vaxart common stock, including 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. This event reflects tax settlement on equity compensation rather than an open-market sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Cummings James F.
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 3,292 | $0.65 | $2K |
Holdings After Transaction:
Common Stock — 924,177 shares (Direct)
Footnotes (1)
- Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.
Key Figures
Shares withheld for taxes: 3,292 shares
Withholding price: $0.65 per share
Shares held after transaction: 924,177 shares
+1 more
4 metrics
Shares withheld for taxes
3,292 shares
Withheld on March 28, 2026 to satisfy RSU tax obligations
Withholding price
$0.65 per share
Value used for 3,292 withheld common shares
Shares held after transaction
924,177 shares
Direct Vaxart common stock holdings following tax withholding
Shares from 2022 ESPP
75,618 shares
Portion of holdings acquired under Vaxart, Inc. 2022 Employee Stock Purchase Plan
Key Terms
RSUs, net settlement, Employee Stock Purchase Plan, income tax withholding
4 terms
RSUs financial
"in connection with the net settlement of RSUs vested as of March 28, 2026"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
net settlement financial
"to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs"
Employee Stock Purchase Plan financial
"includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
income tax withholding financial
"withheld by the Issuer to satisfy its income tax withholding and remittance obligations"
FAQ
What insider transaction did Vaxart (VXRT) report for James F. Cummings?
Vaxart reported that Chief Medical Officer James F. Cummings had 3,292 common shares withheld to cover taxes on vested RSUs. The issuer retained these shares at $0.65 per share as part of equity compensation tax settlement, not an open-market sale.
Was the Vaxart (VXRT) Form 4 transaction an open-market sale by the CMO?
No, the transaction was not an open-market sale. The 3,292 shares of Vaxart common stock were withheld by the company to cover income tax obligations on vested RSUs, a standard compensation-related tax settlement method rather than a discretionary market trade.
What role did RSUs play in the latest Vaxart (VXRT) insider filing?
The Form 4 shows RSUs vested on March 28, 2026, triggering tax obligations. To satisfy these, Vaxart withheld 3,292 common shares at $0.65 per share, using a net settlement approach commonly applied to restricted stock units when they vest.